Briumvi: FDA approved December 2022; anticipated availability is the first quarter of 2023.
Multiple sclerosis, relapsing: Treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
History of life-threatening infusion reaction to ublituximab; active hepatitis B virus (HBV) infection.
